These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 29694792)

  • 1. Response to Trametinib of a Pulmonary Langerhans Cell Histiocytosis Harboring a MAP2K1 Deletion.
    Lorillon G; Jouenne F; Baroudjian B; de Margerie-Mellon C; Vercellino L; Meignin V; Lebbe C; Vassallo R; Mourah S; Tazi A
    Am J Respir Crit Care Med; 2018 Sep; 198(5):675-678. PubMed ID: 29694792
    [No Abstract]   [Full Text] [Related]  

  • 2. Langerhans cell histiocytosis with BRAF p.N486_P490del or MAP2K1 p.K57_G61del treated by the MEK inhibitor trametinib.
    Messinger YH; Bostrom BC; Olson DR; Gossai NP; Miller LH; Richards MK
    Pediatr Blood Cancer; 2020 Dec; 67(12):e28712. PubMed ID: 32991018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical resistance associated with a novel MAP2K1 mutation in a patient with Langerhans cell histiocytosis.
    Azorsa DO; Lee DW; Wai DH; Bista R; Patel AR; Aleem E; Henry MM; Arceci RJ
    Pediatr Blood Cancer; 2018 Sep; 65(9):e27237. PubMed ID: 29768711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trametinib in the treatment of multiple malignancies harboring MEK1 mutations.
    Lian T; Li C; Wang H
    Cancer Treat Rev; 2019 Dec; 81():101907. PubMed ID: 31715422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MEK Inhibition in the Treatment of Congenital Langerhans Cell Histiocytosis: A Case Report and Review of the Literature.
    Wojciechowska N; Burke S; Ray A
    J Pediatr Hematol Oncol; 2024 Oct; 46(7):383-387. PubMed ID: 39101723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comment on: Langerhans cell histiocytosis with BRAF p.N486_P490del or MAP2K1 p.K57_G61del treated by the MEK inhibitor trametinib.
    Vicenzi P; Ray A
    Pediatr Blood Cancer; 2021 Apr; 68(4):e28776. PubMed ID: 33089615
    [No Abstract]   [Full Text] [Related]  

  • 7. Promises from trametinib in RAF active tumors.
    Sausville EA
    N Engl J Med; 2012 Jul; 367(2):171-2. PubMed ID: 22663012
    [No Abstract]   [Full Text] [Related]  

  • 8. A case of recurrent histiocytic sarcoma with MAP2K1 pathogenic variant treated with the MEK inhibitor trametinib.
    Kumamoto T; Aoki Y; Sonoda T; Yamanishi M; Arakawa A; Sugiyama M; Shirakawa N; Ishimaru S; Saito Y; Maeshima A; Maeda M; Ogawa C
    Int J Hematol; 2019 Feb; 109(2):228-232. PubMed ID: 30361829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trametinib for the treatment of IGHV4-34, MAP2K1-mutant variant hairy cell leukemia.
    Andritsos LA; Grieselhuber NR; Anghelina M; Rogers KA; Roychowdhury S; Reeser JW; Timmers CD; Freud AG; Blachly JS; Lucas DM; Lozanski G; Jones JA; Williams K; Oakes C; Jones D; Grever MR
    Leuk Lymphoma; 2018 Apr; 59(4):1008-1011. PubMed ID: 28918710
    [No Abstract]   [Full Text] [Related]  

  • 10. Trametinib in Histiocytic Sarcoma with an Activating MAP2K1 (MEK1) Mutation.
    Gounder MM; Solit DB; Tap WD
    N Engl J Med; 2018 May; 378(20):1945-1947. PubMed ID: 29768143
    [No Abstract]   [Full Text] [Related]  

  • 11. MAP2K1 and MAP3K1 mutations in Langerhans cell histiocytosis.
    Nelson DS; van Halteren A; Quispel WT; van den Bos C; Bovée JV; Patel B; Badalian-Very G; van Hummelen P; Ducar M; Lin L; MacConaill LE; Egeler RM; Rollins BJ
    Genes Chromosomes Cancer; 2015 Jun; 54(6):361-8. PubMed ID: 25899310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trametinib in metastatic melanoma.
    Chopra N; Nathan PD
    Expert Rev Anticancer Ther; 2015; 15(7):749-60. PubMed ID: 26107021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trametinib for a child with refractory Rosai-Dorfman-Destombes disease harboring a novel somatic mutation in MAP2K1.
    Taneyama Y; Morimoto A; Ochiai H; Ando K; Kakuda H; Naruke Y; Yokoi S
    Int J Hematol; 2024 Oct; 120(4):520-524. PubMed ID: 39003680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lasting Complete Clinical Response of a Recurring Cutaneous Squamous Cell Carcinoma With
    Remenár É; Dóczi R; Dirner A; Sipos A; Perjési A; Tihanyi D; Vodicska B; Lakatos D; Horváth K; Kajáry K; Schwáb R; Déri J; Lengyel CG; Várkondi E; Vályi-Nagy I; Peták I
    JCO Precis Oncol; 2022 Jan; 6():e2100344. PubMed ID: 35005996
    [No Abstract]   [Full Text] [Related]  

  • 15. MEK inhibition in BRAF-mutated melanoma.
    Ascierto PA
    N Engl J Med; 2012 Oct; 367(14):1364; author reply 1365. PubMed ID: 23034028
    [No Abstract]   [Full Text] [Related]  

  • 16. MEK inhibition in BRAF-mutated melanoma.
    MacKenzie A; Boycott K
    N Engl J Med; 2012 Oct; 367(14):1364-5. PubMed ID: 23034029
    [No Abstract]   [Full Text] [Related]  

  • 17. Allosteric MEK1/2 inhibitors including cobimetanib and trametinib in the treatment of cutaneous melanomas.
    Roskoski R
    Pharmacol Res; 2017 Mar; 117():20-31. PubMed ID: 27956260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atypical radiological manifestations of pulmonary Langerhans cell histiocytosis in a 12-year-old girl.
    Ko SM; Choe BK; Kim HS; Lee HJ; Kwon KY
    Br J Radiol; 2008 Oct; 81(970):e238-41. PubMed ID: 18796550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progressive diffuse pulmonary Langerhans cell histiocytosis improved by cladribine chemotherapy.
    Lazor R; Etienne-Mastroianni B; Khouatra C; Tazi A; Cottin V; Cordier JF
    Thorax; 2009 Mar; 64(3):274-5. PubMed ID: 19252036
    [No Abstract]   [Full Text] [Related]  

  • 20. Real-time genomic profiling of histiocytoses identifies early-kinase domain BRAF alterations while improving treatment outcomes.
    Lee LH; Gasilina A; Roychoudhury J; Clark J; McCormack FX; Pressey J; Grimley MS; Lorsbach R; Ali S; Bailey M; Stephens P; Ross JS; Miller VA; Nassar NN; Kumar AR
    JCI Insight; 2017 Feb; 2(3):e89473. PubMed ID: 28194436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.